{'fraction_non_alphanumeric': 0.05046728971962617, 'fraction_numerical': 0.02897196261682243, 'mean_word_length': 5.2631578947368425, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A meta‐analysis of stages I and II Hodgkin's disease

To compare radiotherapy alone to chemotherapy plus radiotherapy in the treatment of early stage Hodgkin's disease, the English language medical literature was searched for reports on randomized clinical trials in Stages I and II Hodgkin's disease from 1975 through 1986. Twenty‐three reports with 2999 patients were entered into matched study analysis. Data on extended‐field radiotherapy (EF), involved‐field (IF), chemotherapy alone, combination chemotherapy and radiotherapy (CM), disease stage, laparotomy staging, and complications were gathered. A proportional hazard rate was used to estimate and compare relapse‐free (RFS) and overall survival rates (S). Iteratively reweighted least square analysis was used to estimate survival curves. Twelve‐year RFS for CM (889 patients) was significantly superior to EF (1350 patients) (P < 0.01). Twenty‐year RFS in EF was better than IF (760 patients) (P < 0.01). Twelve‐year S for CM was not significantly different than for EF but was better than for IF (P < 0.05).